1BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection
and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes
using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions
and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications
in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer
patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib).
This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory
site located at 320 Wakara Way, Salt Lake City, UT 84108.
The Science Recent Publications
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Myriad myPlan™ Lung Cancer measures
expression levels of critical cell cycle genes. Combined with pathologic
tumor stage, the result is correlated with the 5-year risk of lung cancer
death—guiding physicians in making
chemotherapy decisions for early-stage patients.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
Beginning July 22, 2013, Myriad will offer financial assistance to reduce qualified underinsured patients’ out-of-pocket cost to no more than $375. To be eligible, patients must have private insurance, meet their insurance’s coverage criteria for testing, and meet low income requirements (household incomes up to 200 percent of the Federal poverty level). This expansion of Myriad’s financial assistance program to underinsured patients complements the free testing Myriad currently offers for low income uninsured patients.
Myriad offers testing at no charge to uninsured patients that meet specific financial and medical criteria. Patients with insurance that meet similar financial and medical criteria may be eligible for financial assistance through Myriad. Due to regulatory limitations, patients who are recipients of government funded programs (ie, Medicaid, Medicare) are not eligible to apply for MFAP.
Qualification requirements and the submission instructions are provided below:
With the Myriad Promise, we partner to ensure your satisfaction.
At Myriad, we believe every patient should have access to the highest quality genetic testing because we know how useful it is in helping healthcare providers deliver the best medical care.
When one of our tests is ordered for you, we will work with your insurance provider to help you get the appropriate coverage allowed by your plan.
If your out of pocket expense will exceed $375, we will call you before processing your test to discuss payment plan options that are available to you.
We won’t call if your bill will be $375 or less, but if you have concerns about your bill, you can contact us at the 800 number that appears on your bill and we guarantee that we will work with you to come up with an option that’s right for you.
We are committed to make sure that test results are accurate, timely, and financially accessible to everyone.
What does this mean for you?
When your doctor feels you should have genetic testing to help you get the best possible care, you can proceed right away, feeling confident that the costs will be manageable.
No surprises. If your bill will be more than $375, we’ll call. You can work with us to come up with a payment plan that meets your needs.
Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.